Integrase Inhibitors: all 515 studies that test it

Page 2 of 6. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV InfectionCompletedNCT03205566Phase 4Results posted
• Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenActive, not recruitingNCT03164564Phase 3Results posted
• Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy SubjectsCompletedNCT03149848Phase 1Results posted
• Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedCompletedNCT03110380Phase 3Results posted
• Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and LamivudineCompletedNCT03078556Phase 1Results posted
• Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their InfantsCompletedNCT03048422Phase 3Results posted
• Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDYCompletedNCT03029689Phase 3Results posted
• Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019CompletedNCT03016533Phase 3Results posted
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingNCT02951052Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingNCT02938520Phase 3Results posted
• Dolutegravir in ReservoirsTerminatedNCT02924389Phase 4Results posted
• Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenCompletedNCT02720094Phase 2/3Results posted
• Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentCompletedNCT02707601Phase 3Results posted
• Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedNCT02652624Phase 3Results posted
• Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsCompletedNCT02616783Phase 3Results posted
• Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184ICompletedNCT02616029Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607956Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02607930Phase 3Results posted
• Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsCompletedNCT02605954Phase 3Results posted
• Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedCompletedNCT02603120Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisCompletedNCT02600819Phase 3Results posted
• Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 PatientsCompletedNCT02582684Phase 2Results posted
• Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based RegimenCompletedNCT02577042Phase 4Results posted
• Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)CompletedNCT02519777Phase 4Results posted
• Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult VolunteersCompletedNCT02478463Phase 1Results posted
• The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)CompletedNCT02473367Phase 1Results posted
• HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02437110Phase 1Results posted
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)CompletedNCT02429791Phase 3Results posted
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)CompletedNCT02422797Phase 3Results posted
• Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative VolunteersCompletedNCT02404805Not applicableResults posted
• Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal FunctionCompletedNCT02400307Phase 1Results posted
• Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT02397694Phase 2Results posted
• Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV InfectionCompletedNCT02384395Not applicableResults posted
• Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune ActivationCompletedNCT02383355Phase 4Results posted
• Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineCompletedNCT02284035Phase 3Results posted
• Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected AdolescentsCompletedNCT02276612Phase 2/3Results posted
• Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected ParticipantsCompletedNCT02275065Phase 1Results posted
• Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug ExposureCompletedNCT02263326Phase 3Results posted
• ODYSSEY (PENTA 20)CompletedNCT02259127Phase 2/3Results posted
• Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot StudyCompletedNCT02245022Phase 2/3Results posted
• Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line TreatmentCompletedNCT02227238Phase 3Results posted
• Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALCompletedNCT02212379Phase 2Results posted
• Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected AdultsCompletedNCT02178800Phase 2Results posted
• Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infectionCompletedNCT02178592Phase 3Results posted
• A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult SubjectsCompletedNCT02120352Phase 2Results posted
• Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedNCT02116660Phase 2Results posted
• Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to RaltegravirCompletedNCT02097108Phase 2Results posted
• ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus InfectionCompletedNCT02075593Phase 3Results posted
• Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected AdultsCompletedNCT02071082Phase 3Results posted
• Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 PatientsCompletedNCT01989910Phase 4Results posted
• Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based RegimenCompletedNCT01978743Not applicableResults posted
• Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedNCT01968551Phase 3Results posted
• Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsCompletedNCT01967940Phase 3Results posted
• A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)CompletedNCT01930045Phase 1Results posted
• Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric ParticipantsTerminatedNCT01923311Phase 2/3Results posted
• A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedNCT01910402Phase 3Results posted
• Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV InfectionTerminatedNCT01854762Phase 2/3Results posted
• A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy VolunteersCompletedNCT01841593Phase 1Results posted
• Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS PatientsCompletedNCT01837277Phase 2/3Results posted
• Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentCompletedNCT01818596Phase 3Results posted
• Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedNCT01815736Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01797445Phase 3Results posted
• The Effect of Antacids and Multivitamins on RaltegravirCompletedNCT01784302Phase 1Results posted
• Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 InfectionCompletedNCT01780831Phase 1Results posted
• Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedNCT01780506Phase 3Results posted
• Raltegravir (Isentress) Pilot Study in Relapsing Multiple SclerosisCompletedNCT01767701Phase 2Results posted
• Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TBCompletedNCT01751568Phase 1/2Results posted
• A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)CompletedNCT01717287Phase 2Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral FailureCompletedNCT01641367Phase 4Results posted
• A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)CompletedNCT01622673Phase 1Results posted
• Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child TransmissionCompletedNCT01618305Phase 4Results posted
• Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIVTerminatedNCT01601626Phase 2Results posted
• Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or ElivitegravirCompletedNCT01568892Phase 3Results posted
• Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively TreatedCompletedNCT01529749Phase 4Results posted
• Bone and Body Comp: A Sub Study of the SECOND-LINE StudyCompletedNCT01513122Phase 4Results posted
• A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive SubjectsCompletedNCT01499199Phase 3Results posted
• Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01497899Phase 2Results posted
• A Key Link for Transmission PreventionCompletedNCT01450189Not applicableResults posted
• Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsCompletedNCT01449929Phase 3Results posted
• A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIVTerminatedNCT01448486Phase 4Results posted
• Study of Options for Second-Line Effective Combination Therapy (SELECT)CompletedNCT01352715Phase 3Results posted
• The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of AgeCompletedNCT01335620Phase 4Results posted
• Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected PatientsCompletedNCT01332227Phase 4Results posted
• A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.CompletedNCT01328041Phase 3Results posted
• Levels of Raltegravir in the Female Genital TissueCompletedNCT01327482Not applicableResults posted
• Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and AdolescentsCompletedNCT01302847Phase 1/2Results posted
• Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected IndividualsTerminatedNCT01293123Not applicableResults posted
• Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected PatientsCompletedNCT01270802Phase 4Results posted
• Addition of Raltegravir to Established Antiretroviral Suppressive TherapyTerminatedNCT01245101Phase 4Results posted
• A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive AdultsCompletedNCT01231516Phase 3Results posted
• A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyCompletedNCT01227824Phase 3Results posted
• Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)CompletedNCT01214759Phase 4Results posted
• R5 Integrase Study in HIV-1 Naive PatientsCompletedNCT01204905Not applicableResults posted
• Atripla to Raltegravir Switch Study for CNS ToxicityCompletedNCT01195467Phase 3Results posted
• Effects of Intensive cART During Acute/Early HIV InfectionCompletedNCT01154673Phase 2/3Results posted
• Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV CoinfectionCompletedNCT01147107Phase 4Results posted
• Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced ProteinuriaCompletedNCT01044771Not applicableResults posted
• HIV Persistence and Viral ReservoirsCompletedNCT01025427Phase 4Results posted
• The Raltegravir and Ribavirin Pharmacokinetics (PK) StudyCompletedNCT00982553Phase 1Results posted

← Integrase Inhibitors overview